Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Transgene S.A.. (4/10/17). "Press Release: Transgene Announces Upcoming Investor Meetings and R&D Day". Strasbourg.

Region Region Amsterdam
  Country Netherlands
Organisations Organisation Transgene S.A. (Euronext: TNG)
  Group Mérieux (Group)
  Organisation 2 Kempen & Co. N.V.
  Group Van Lanschot (Group)
Products Product Kempen Life Sciences Conference 2017 Amsterdam
  Product 2 TG4010 (MVA-MUC1-IL2) (Transgene)
Index terms Index term Mérieux–Van Lanschot: investor conference, 201704 supply service Transgene SA presents at Kempen Life Sciences Conference
  Index term 2 Mérieux–Kepler Chevreux: investor conference, 201706 supply service Transgene SA presents at Kepler Biotech Days 2017 in Paris
Persons Person Larguier, Lucie (Mérieux 201704 Director CorpComm + IR at Transgene before Citigate Dewe Rogerson Paris)
  Person 2 Perrier, Marine (Enterome 202103 Head of External Communications + IR before Citigate Dewe Rogerson)

Transgene today announced that management will participate in the upcoming investor events set out below.

• Kempen 10th Life Sciences Conference: April 19, 2017 - Amsterdam, Netherlands

• Kepler Biotech Days: June 9, 2017 - Paris, France

Transgene will host a “R&D Day”, on June 22, 2017 in Paris, France. The event which will be conducted in English will feature presentations from several leading international scientists and clinicians.

Next scheduled financial communication
1st quarter 2017 business update
April 25, 2017 after market close


Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04

Media contacts: Citigate Dewe Rogerson
David Dible / Marine Perrier
+ 44 (0)20 7638 9571

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at

Follow us on Twitter: @TransgeneSA

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Mérieux (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top